Adcock Ingram

Adcock Ingram is a leading South African pharmaceutical manufacturer listed on the Johannesburg Stock Exchange.

The Company manufactures, markets, and distributes a wide range of healthcare products and is a leading supplier to both the private and public sectors of the market. Through the recent acquisition of Plush the Company expanded into the Homecare market.

Adcock Ingram is a level two B-BBEE contributor.

Adcock Ingram is ranked as the second largest manufacturer in the private pharmaceutical market and is the second largest supplier to the public sector. Of note is the major share of the critical care market held by the company, being the largest supplier of critical care products to the public sector and hospitals. Adcock Ingram is a committed supplier of antiretroviral (ARV) medicines to the public sector through the highly competitive tender system.

The Consumer division competes mainly in the unregulated Fast Moving Consumer goods (FMCG) market. Products are also distributed and marketed in modern and traditional trade outlets. It continues to focus on the marketing, selling and distribution of healthcare, personal care and homecare brands. The well-known Epi-max skin care range was transferred from the Prescription division on 1 January 2021.